ABSTRACT
International guidelines recommend using local susceptibility data to direct empiric therapy for acute uncomplicated cystitis. We evaluated outpatient urinary isolate susceptibility trends in New York State. Nitrofurantoin had the lowest resistance prevalence whereas trimethoprim-sulfamethoxazole and fluoroquinolones had higher prevalences. This study highlights the need for local outpatient antimicrobial stewardship programs.
ABSTRACT
BACKGROUND: Performances of the BD ProbeTec Chlamydia trachomatis (CT)/Neisseria Gonorrhoeae (GC) Q(x) Amplified DNA Assay reagents on a BD Viper System with XTR Technology and APTIMA COMBO 2 Assay reagents on a TIGRIS DTS platform, for detection of both CT and GC were compared. METHODS: A total of 1018 first-void urine specimens were tested for the presence of CT and GC DNA using the 2 assays. RESULTS: CT was detected in 143 specimens (14%). Eight specimens exhibited discordant results, and they were divided equally between the 2 assays. Based on the original results, the overall agreement for CT was 99.2%, with 97.1% and 99.5% in agreement with positive and negative specimens, respectively. Cohen's Kappa was 0.967. GC was detected in 27 specimens (2.6%). Two specimens exhibited discordant results, and they were divided equally between the 2 assays. Based on the original results, the overall agreement was 99.8%, with 96.2% and 99.9% in agreement for positive and negative specimens, respectively. Cohen's Kappa was 0.961. CONCLUSIONS: There was a high level of agreement between the systems for both CT and GC detection.
Subject(s)
Chlamydia Infections/urine , Chlamydia trachomatis/isolation & purification , Gonorrhea/urine , Neisseria gonorrhoeae/isolation & purification , Nucleic Acid Amplification Techniques/methods , Algorithms , Automation, Laboratory/instrumentation , Automation, Laboratory/methods , Bacterial Typing Techniques/methods , Chlamydia Infections/microbiology , Chlamydia trachomatis/genetics , Female , Gonorrhea/microbiology , Humans , Male , Molecular Diagnostic Techniques/methods , Neisseria gonorrhoeae/genetics , Nucleic Acid Amplification Techniques/instrumentation , Reagent Kits, Diagnostic , Saskatchewan , Sensitivity and SpecificityABSTRACT
The BD ProbeTec CT Q(x) Amplified DNA Assay and the BD ProbeTec GC Q(x) Amplified DNA Assay (both BD Diagnostics, Sparks, MD) represent two new assays developed for use with the BD Viper System with XTR Technology (BD Diagnostics). These assays were built on the foundation of the former BD ProbeTec ET assays (BD Diagnostics) and its accompanying instrumentation. The study described below compared the new assay format, Extracted Mode, to the former assay format, Nonextracted Mode, with the primary objective of examining and measuring overall time expenditures and efficiency of operation. An 80-142-min reduction in "hands-on" total processing time was observed for the Extracted Mode whether testing urines or swabs. The second objective was to assess the accuracy of performance at low simulated analytical loads for the pathogens Chlamydia trachomatis and Neisseria gonorrhoeae. Performance accuracies for simulated positive and negative urine or swab specimens were calculated to be 99.97% for Extracted Mode and 99.76% for Nonextracted Mode.